Navigation Links
Trastuzumab therapy effective for Breast cancer patients with Her-2/neu positive

Researchers Edith Perez and Edward Romond reported from two separate trials that Breast cancer patients with Her2-positive were effectively treated with Herceptin therapy using trastuzumab. //The results of their study were published in the journal The New England Journal of Medicine. The researchers compiled results from two clinical trials, which compared patients getting only chemotherapy with patients receiving both chemotherapy and trastuzumab. Use of Herceptin drug has become very important as more than one million women are diagnosed of breast cancer each year around the world and of which 25% of patients have Her-2/neu positive status. Her-2 positive patients do not respond positively and effectively to routine chemotherapy drugs, which require trastuzumab therapy.

The study recruited a total of 3,351 patients of which 2,043 patients were enrolled in National Surgical Adjuvant Breast and Bowel Project (NSABP) and 1,633 patients were enrolled in two groups of North Central Cancer Treatment Group (NCCTG) trial N9831. The study results showed that out of 1,679 control patients 261 patients developed recurrence breast cancer disease compared to 133 in the group receiving trastuzumab. At three years, 90.4 percent of women receiving trastuzumab were disease free, compared to 81.5 percent of women in the control group. There also was a measurable reduction in the development of other non-breast primary cancers in the B-31 trial for women receiving trastuzumab. Overall survival also appeared to be impacted, with only 62 deaths in the trastuzumab group as compared with 92 in the control group.

NCCTG Trial: NCCTG trial was investigated by Dr. Perez and his team, the clinical trial compared three chemotherapy drugs treatment of which two of the drug treatments contained trastuzumab therapy with one dosage concurrent with weekly paclitaxel, the other after completion of paclitaxel.

NSABP Trial: Investigators compared treatment with o ne chemotherapy regimen against the same chemotherapy regimen of weekly trastuzumab and weekly paclitaxel. Dr. Perez, Co-director Mayo Clinic’s Multidisciplinary Breast Clinic said, “When we started this study, I knew in my heart results would be positive, but this by far exceeded my expectations and now there is convincing evidence that women with Her-2/neu positive breast cancer can now be treated more effectively.”

Source: News wis
'"/>




Related medicine news :

1. Acupuncture May Help Chemotherapy Side Effects
2. Antioxidants protect health tissue in people undergoing radiation therapy.
3. Distraction therapy found very effective in postoperative patients
4. Acupuncture superseeds massage therapy for short term relief of pain
5. Ovarian cancer in relationship with Hormone therapy
6. New therapy better at increasing bone density
7. Gene therapy - Aim to improve blood flow
8. Gene therapy restores sight
9. Heat therapy relieves back pain
10. Radiotherapy helps in colon cancer
11. New therapy for pimples
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/2/2016)... ... May 02, 2016 , ... “Engineering Bubbles,” an oil painting submitted ... ARRS Art Forum held recently at the Annual Meeting in Los Angeles. The first ... ARRS members and Annual Meeting attendees. , “Through art I hope to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Over $60 Billion is spent ... pet gear and toys, leading product review site for Toys, Tots, Pets & More ... at their Spring Showcase at the Metropolitan Pavilion in New York City. , ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... has announced a new Specialty Pharmacy Patient Satisfaction Award that will recognize specialty ... the quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled ...
(Date:5/2/2016)... ... ... According to an American Psychological Association article, the Centers for Disease ... of 18. Of those who survive, many still face effects as they reach adulthood. ... new book, Lyah! Lyah! Pants on Fyah!, she shares stories from women who are ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... Research & Analytics EVP and GM Jim Callandrillo and Duane Reed, VP ... 55th Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... NEW YORK , May 2, 2016 /PRNewswire/ ... Series B financing of Graybug Vision, Inc. Graybug ... to developing therapies that may transform care for ... and glaucoma.  Graybug Vision,s technology was first developed ... out into a startup venture. ...
(Date:4/29/2016)... 2016  In the next ten years, the ... systems dependent on CRTs monitors to those reliant on ... Medical monitors and will automatically sync to existing ... foreseeable benefits to this technological advancement, it also ... to be replaced in order to be LCD ...
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
Breaking Medicine Technology: